Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
10.58
+0.13 (1.20%)
At close: Nov 20, 2024, 4:00 PM
10.25
-0.33 (-3.12%)
After-hours: Nov 20, 2024, 7:17 PM EST
Indivior Revenue
Indivior had revenue of $307.00M in the quarter ending September 30, 2024, with 13.28% growth. This brings the company's revenue in the last twelve months to $1.18B, up 13.44% year-over-year. In the year 2023, Indivior had annual revenue of $1.09B with 21.31% growth.
Revenue (ttm)
$1.18B
Revenue Growth
+13.44%
P/S Ratio
n/a
Revenue / Employee
$1,015,464
Employees
1,164
Market Cap
1.33B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
Dec 31, 2019 | 785.00M | -220.00M | -21.89% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.26B |
Pediatrix Medical Group | 2.01B |
Novavax | 885.19M |
Tilray Brands | 812.04M |
Alphatec Holdings | 572.74M |
Mesoblast | 5.90M |
INDV News
- 1 day ago - Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 - PRNewsWire
- 13 days ago - Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior - PRNewsWire
- 21 days ago - Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month - PRNewsWire
- 27 days ago - Indivior PLC (INDV) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Indivior Announces Q3 2024 Financial Results - PRNewsWire
- 5 weeks ago - Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 - Seeking Alpha
- 6 weeks ago - British drugmaker Indivior cuts 2024 revenue forecast, shares fall - Reuters
- 6 weeks ago - Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion - PRNewsWire